Cardiac drug’s patent off, desi firms offer cheaper version | India News

MUMBAI: People suffering from cardiac problems can look forward to substantial savings in their healthcare budget. Several domestic companies including Glenmark and Lupin have launched generic versions of blockbuster cardiology drug Valsartan at a fraction of the price sold by the innovator, Novartis. Others like Torrent, Cipla and Sun Pharma are expected to follow suit. The drug lost its patent protection on January 16.
Dr Reddy’s and JB Chemicals, companies which had acquired the cardiovascular brand from Novartis last year, have also announced significant price reductions on Cidmus and Azmarda, respectively. Mumbai-based JB Chemicals was one of the first companies to have announced aprice reduction on Azmardaby around 50% in December to Rs 40 per tablet (50 mg).
Around 12 to 15 companies are expected to enter the Rs 24,000 crore space to get a slice of the opportunity by the month-end. With competition intensifying over the next few months, further price reductions are expected, industry experts say.
TOIwas the first to write about this in its edition dated December3.
The drug, growing at nearly 40% CAGR, is one of the fastest growing mole-cules in the cardiology segment. The combination, Valsartan and Sacubitril which was under patent from Novartis, is indicated for heart failure patients with ‘reduced ejection fraction’.
The Swiss firm markets the heart failure drug as Entresto, which generated around $4 billion sales worldwide. Cardiovascular diseases (CVD) are the leading cause of death globally. World Health Organisation (WHO) estimates that by 2030, CV will account for over 35% of all deaths in India (as compared to 25% as of 2016).
Heart failure is a progressive chronic syndrome characterised by a decrease in functional status and quality of life. The burden of heart failure is experienced by an estimated 23 million people worldwide.
In India, the prevalence is estimated to be about 1% of the population.

#Cardiac #drugs #patent #desi #firms #offer #cheaper #version #India #News

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button